Preview

Obesity and metabolism

Advanced search

The prevalence of metabolically healthy obesity according to the sample of the Moscow region

https://doi.org/10.14341/omet2017451-56

Abstract

Introduction. Obesity is a major factor for cardiometabolic risk. However, there is a category of obese patients without disorders of lipid, carbohydrate metabolism and cardiovascular disease – metabolically healthy obese (MHO).


Aim. Our goal was to investigate the prevalence and characteristics of this phenotype compared to patients with metabolic syndrome (MS).


Materials and methods. To evaluate the prevalence of the MHO phenotype we analyzed 389 medical records of females aged 18–60 years with obesity. Three types of MHO criteria were used: 1) HOMA index (<2.7); 2) IDF-criteria of metabolic syndrome, 2005; 3) the BioSHaRE-EU 2013 criteria (obese patients without any symptoms of MS). We conducted a comparative analysis of anthropometry, status of lipid and carbohydrate metabolism, the functional state of the liver.


Results. The MHO prevalence was: 34.5% according to HOMA index, according to the definitions of MS 2005 – 38.6%, in BioSHaRE-EU – 9.6%. In groups of MHO and MS dyslipidemia was observed in 27.3 and 49.5% (p<0.05), hypertension in 25% and 71.6% (p<0.05), steatogepatosis in 47.7% vs 51.3% (p<0.05) of observations, respectively. Among comorbidities the gynecological pathology was most prevalent - 50.8 and 61.4% (p<0.05), disorders of carbohydrate metabolism differed significantly in frequency- 6.82 and 39.1% of patients (p<0.05). Patients with MHO had a shorter duration of the existence of obesity than MS (18.7 vs. 24 years) (p=0.0004) and less likely to have attempted to reduce weight – 85.8% and 91.6%. Average BMI, waist circumference, hip circumference, fasting glucose, total cholesterol, insulin basal, basal C-peptide, HOMA index in groups of MHO and MS differed significantly (p<0.05). Median ALT was 20 and 23.2 U/l, AST – 20 and 23 U/l, triglycerides – 1.1 and 1.8 mmol/l, high-density lipoprotein – 1.4 and 1.1 mmol/l, respectively.


Conclusions. The MHO prevalence was maximal according to the MS definitions from 2005, and minimal with BioSHaRE-EU criteria. The main analyzed indicators differed significantly in groups MHO and MS. Longer obesity existence in the MS group may suggest an instability of MHO phenotype over time.

About the Authors

Elena V. Ostrovskaya

I.M.Sechenov First Moscow State Medical University


Russian Federation

postgraduate student


Competing Interests:

The author states that there are no obvious and potential conflicts of interest related to the publication of this article



Tatiana I. Romantsova

I.M.Sechenov First Moscow State Medical University


Russian Federation

ScD, professor 


Competing Interests:

The author states that there are no obvious and potential conflicts of interest related to the publication of this article



Andrei N. Gerasimov

I.M.Sechenov First Moscow State Medical University


Russian Federation

Doctor of physico-mathematical sciences, professor 


Competing Interests:

The author states that there are no obvious and potential conflicts of interest related to the publication of this article



Tamara E. Novoselova

I.M.Sechenov First Moscow State Medical University


Russian Federation

Senior teacher of the department of medical informatics and statistics 


Competing Interests:

The author states that there are no obvious and potential conflicts of interest related to the publication of this article



References

1. Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. The Lancet. 2014;384(9945):766-781. doi: 10.1016/s0140-6736(14)60460-8.

2. Alam I, Ng TP, Larbi A. Does Inflammation Determine Whether Obesity Is Metabolically Healthy or Unhealthy? The Aging Perspective. Mediators Inflamm. 2012;2012:1-14. doi: 10.1155/2012/456456.

3. Messier V, Karelis AD, Prud'homme D, et al. Identifying Metabolically Healthy but Obese Individuals in Sedentary Postmenopausal Women. Obesity. 2009;18(5):911-917. doi: 10.1038/oby.2009.364.

4. Stefan N. Identification and Characterization of Metabolically Benign Obesity in Humans. Arch Intern Med. 2008;168(15):1609. doi: 10.1001/archinte.168.15.1609.

5. Lind L, Siegbahn A, Ingelsson E, et al. A Detailed Cardiovascular Characterization of Obesity Without the Metabolic Syndrome. Arterioscler Thromb Vasc Biol. 2011;31(8):e27-e34. doi: 10.1161/atvbaha.110.221572.

6. van Vliet-Ostaptchouk JV, Nuotio M-L, Slagter SN, et al. The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. BMC Endo Dis. 2014;14(1). doi: 10.1186/1472-6823-14-9.

7. Rey-López JP, de Rezende LF, Pastor-Valero M, Tess BH. The prevalence of metabolically healthy obesity: a systematic review and critical evaluation of the definitions used. Obes Rev. 2014;15(10):781-790. doi: 10.1111/obr.12198.

8. Wildman RP. The Obese Without Cardiometabolic Risk Factor Clustering and the Normal Weight With Cardiometabolic Risk Factor Clustering. Arch Intern Med. 2008;168(15):1617. doi: 10.1001/archinte.168.15.1617.

9. Rotar O, Konradi A, Shalnova S, et al. [Op.2a.03] Metabolically Healthy Obesity and Metabolically Obese Normal Weight in Russian Population. J Hypertens. 2016;34:e16. doi: 10.1097/01.hjh.0000491368.63715.51.

10. Berezina A, Belyaeva O, Berkovich O, et al. Prevalence, Risk Factors, and Genetic Traits in Metabolically Healthy and Unhealthy Obese Individuals. BioMed Research International. 2015;2015:1-9. doi: 10.1155/2015/548734.


Supplementary files

1. Рис. 1. Распространенность МЗО и МС с учетом использования различных критериев.
Subject
Type Исследовательские инструменты
View (119KB)    
Indexing metadata ▾
2. Рис. 2. Частота жалоб пациенток в группе МЗО и МС.
Subject
Type Исследовательские инструменты
View (82KB)    
Indexing metadata ▾
3. Рис. 3. Структура коморбидностей в группах МЗО и МС.
Subject
Type Исследовательские инструменты
View (67KB)    
Indexing metadata ▾
4. Рис. 4. Различия основных показателей в группах пациентов с МЗО и МС.
Subject
Type Исследовательские инструменты
View (117KB)    
Indexing metadata ▾

Review

For citations:


Ostrovskaya E.V., Romantsova T.I., Gerasimov A.N., Novoselova T.E. The prevalence of metabolically healthy obesity according to the sample of the Moscow region. Obesity and metabolism. 2017;14(4):51-56. (In Russ.) https://doi.org/10.14341/omet2017451-56

Views: 1270


ISSN 2071-8713 (Print)
ISSN 2306-5524 (Online)